Disease · MONDO_0100244
Comparisons in its trials38
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 38
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ravulizumab IV/SC Treatment Group vs Ravulizumab SC/SC Treatment Group: deaths from any cause | 2 of 45 | 2 of 84 | 129 | NCT03748823 | Trial comparisons |
| Ravulizumab IV/SC Treatment Group vs Ravulizumab SC/SC Treatment Group: serious adverse events | 16 of 45 | 30 of 84 | 129 | NCT03748823 | Trial comparisons |
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants That Remained Disease-free Survival | 26 of 43 | 56 of 57 | 100 | NCT00003838 | Trial comparisons |
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants Who Experienced Transplant Related Mortality | 5 of 43 | 4 of 57 | 100 | NCT00003838 | Trial comparisons |
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality vs Group B: Stem Cell Transplant in Debilitating Hematologic Diseases: Number of Participants Overall Survival | 17 of 43 | 48 of 57 | 100 | NCT00003838 | Trial comparisons |
| SB12 vs Soliris: deaths from any cause | 0 of 47 | 1 of 47 | 94 | NCT04058158 | Trial comparisons |
| SB12 vs Soliris: serious adverse events | 3 of 47 | 2 of 47 | 94 | NCT04058158 | Trial comparisons |
| Overall Pegcetacoplan vs Standard of Care: deaths from any cause | 1 of 46 | 1 of 18 | 64 | NCT04085601 | Trial comparisons |
| Overall Pegcetacoplan vs Standard of Care: serious adverse events | 6 of 46 | 3 of 18 | 64 | NCT04085601 | Trial comparisons |
| Pegcetacoplan vs Standard of Care: Number of Subjects With an Hb Response in the Absence of Transfusions | 25 of 35 | 1 of 18 | 53 | NCT04085601 | Trial comparisons |
| Pegcetacoplan vs Standard of Care: Number of Subjects With Failure of Hb Stabilization | 4 of 35 | 18 of 18 | 53 | NCT04085601 | Trial comparisons |
| Pegcetacoplan vs Standard of Care: Number of Subjects Who Achieved Hemoglobin (Hb) Stabilization | 30 of 35 | 0 of 18 | 53 | NCT04085601 | Trial comparisons |
| Isolex vs CLINIMACs: Number of Patients Who Engrafted With the Isolex/CLINIMACs System | 15 of 19 | 7 of 8 | 27 | NCT00058825 | Trial comparisons |
| Cohort A (Treatment Naive) vs Cohort B (Previously on Eculizumab): deaths from any cause | 0 of 10 | 0 of 16 | 26 | NCT03078582 | Trial comparisons |
| Cohort A (Treatment Naive) vs Cohort B (Previously on Eculizumab): serious adverse events | 2 of 10 | 1 of 16 | 26 | NCT03078582 | Trial comparisons |
| Cohort 1 vs Cohort 2: Number of Subjects Receiving Red Blood Cell (RBC) Transfusions | 1 of 3 | 7 of 20 | 23 | NCT02588833 | Trial comparisons |
| Cohort 1 vs Cohort 2: deaths from any cause | 0 of 3 | 1 of 20 | 23 | NCT02588833 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 1 of 3 | 6 of 20 | 23 | NCT02588833 | Trial comparisons |
| 24-Week Treatment Period: Danicopan + Eculizumab vs LTE Period: Danicopan + Eculizumab: deaths from any cause | 0 of 12 | 0 of 11 | 23 | NCT03472885 | Trial comparisons |
| 24-Week Treatment Period: Danicopan + Eculizumab vs LTE Period: Danicopan + Eculizumab: serious adverse events | 2 of 12 | 7 of 11 | 23 | NCT03472885 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100244/comparisons